ReviewJournal of eating disorders2017
Assessment and clinical management of bone disease in adults with eating disorders: a review.
Review in Journal of eating disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Understanding Bone Density Loss in Eating Disorders: Contributions of Weight Suppression and Speed of Weight Loss.Journal of clinical medicine · 2024Article
- Temporal Profiling of Epitranscriptomic Modulators during Osteogenic Differentiation of Human Embryonic Stem Cells.Journal of proteome research · 2023Article
- Transition of young adults with metabolic bone diseases to adult care.Frontiers in endocrinology · 2023Review
- Medical considerations in the care of transgender and gender diverse patients with eating disorders.Journal of eating disorders · 2022Review
- Subjective Experience of Antidepressant Prescription Among Adolescents With Anorexia Nervosa.Frontiers in psychiatry · 2022Article
- Bone health in functional hypothalamic amenorrhea: What the endocrinologist needs to know.Frontiers in endocrinology · 2022Review
- Reframing anorexia nervosa as a metabo-psychiatric disorder.Trends in endocrinology and metabolism: TEM · 2021Review
- Anorexia nervosa: COVID-19 pandemic period (Review).Experimental and therapeutic medicine · 2021Review
- Abnormal bone mineral density and content in girls with early-onset anorexia nervosa.Journal of eating disorders · 2021Review
- Extreme anorexia nervosa: medical findings, outcomes, and inferences from a retrospective cohort.Journal of eating disorders · 2020Article
- Medication in AN: A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews.Journal of clinical medicine · 2019Review
- Factors influencing bone loss in anorexia nervosa: assessment and therapeutic options.RMD open · 2019Review
- Weight loss practice, nutritional status, bone health, and injury history: A profile of professional jockeys in Korea.Journal of exercise nutrition & biochemistry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo review current medical literature regarding the causes and clinical management options for low bone mineral density (BMD) in adult patients with eating disorders.
backgroundLow bone mineral density is a common complication of eating disorders with potentially lifelong debilitating consequences. Definitive, rigorous guidelines for screening, prevention and management are lacking. This article intends to provide a review of the literature to date and current options for prevention and treatment.
methodsCurrent, peer-reviewed literature was reviewed, interpreted and summarized.
conclusionAny patient with lower than average BMD should weight restore and in premenopausal females, spontaneous menses should resume. Adequate vitamin D and calcium supplementation is important. Weight-bearing exercise should be avoided unless cautiously monitored by a treatment team in the setting of weight restoration. If a patient has a Z-score less than expected for age with a high fracture risk or likelihood of ongoing BMD loss, physiologic transdermal estrogen plus oral progesterone, bisphosphonates (alendronate or risedronate) or teriparatide could be considered. Other agents, such as denosumab and testosterone in men, have not been tested in eating-disordered populations and should only be trialed on an empiric basis if there is a high clinical concern for fractures or worsening bone mineral density. A rigorous peer-based approach to establish guidelines for evaluation and management of low bone mineral density is needed in this neglected subspecialty of eating disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.